晚期恶性黑色素瘤的靶向及免疫治疗研究进展

Progress of targeted therapy and immunotherapy for advanced melanoma

黑色素瘤是一种恶性程度极高的实体肿瘤,易早期发生转移,晚期患者预后极差。近年来,恶性黑色素瘤的发病率和死亡率日益增加并呈年轻化趋势,而我国每年死亡病例与新发病例的比例明显高于全球平均水平,且我国黑色素瘤患者的病理类型及基因突变情况等与国外也有较大差异。目前,随着对该病发病机制研究的逐步深入及生物技术的不断进展,靶向及免疫治疗为改善晚期黑色素瘤患者的预后带来了希望。本文就目前恶性黑色素瘤的靶向、免疫及两者联合治疗的研究情况进行综述。

Malignant melanomaone of the high-grade malignant tumors,is easy to metastasize in early stage and has a dismal prognosis for advanced patients.In recent years,the morbidity and mortality of melanoma have been increasing sharply and the age of onset to incline to the young,while the proportion of deaths and new cases of our country is significantly higher than the global average and the pathological type and genetic mutation are also significantly different from abroad.Now,with the progress of various studies on pathogenesis of melanoma and biotechnology,targeted therapy and immunotherapy bring hopes to the patients with advanced melanoma.This paper made an elaboration on the latest clinical advances in targeted therapy,immunotherapy and combination therapy of malignant melanoma.